PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
Study Details
Study Description
Brief Summary
The purpose of this clinical investigation is to evaluate the accuracy of the Eversense® continuous Glucose Monitoring System (Eversense® 180 CGM System) measurements when compared with reference standard measurements up to 180 days of sensor use.
The investigation will also evaluate safety of the Eversense® 180 CGM System usage.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Continuous Glucose Monitoring Device The Eversense® 180 CGM System |
Device: Continuous Glucose Monitoring System
The Eversense® 180 CGM System
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Effectiveness Measure - mean absolute relative difference (MARD) [180 days]
The effectiveness endpoint will be mean absolute relative difference (MARD) for paired Sensor and reference measurements through 180 days post-insertion for reference glucose values from 40-400 mg/dL.
- Safety Endpoint - Incidence of device-related or sensor insertion/removal procedure-related serious adverse [180 days]
Incidence of device-related or sensor insertion/removal procedure-related serious adverse events through 180 days post-Sensor insertion or removal and follow-up.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult subjects, age ≥18 years
-
Clinically confirmed diagnosis of diabetes mellitus for ≥1 year
-
Subject has signed an informed consent form and is willing to comply with protocol requirements
Exclusion Criteria:
-
History of unexplained severe hypoglycemia in the previous 6 months. Severe hypoglycemia is defined as hypoglycemia resulting in loss of consciousness or seizure
-
History of diabetic ketoacidosis requiring emergency room visit or hospitalization in the previous 6 months
-
Subjects with gastroparesis
-
Female subjects of childbearing capacity (defined as not surgically sterile or not menopausal for ≥ 1 year) who are lactating or pregnant, intending to become pregnant, or not practicing birth control during the course of the study.
-
A condition preventing or complicating the placement,operation, or removal of the Sensor or wearing of transmitter, including upper extremity deformities or skin condition.
-
Symptomatic coronary artery disease; unstable angina; myocardial infarction, transient ischemic attack or stroke in the past 6 months; uncontrolled hypertension (systolic>160 mm Hg or diastolic >100 mm Hg at time of screening); current congestive heart failure; history of cardiac arrhythmia (benign PACs and PVCs allowed). Subjects with asymptomatic coronary artery disease (e.g. CABG, stent placement or angioplasty) may participate if negative stress test within 1 year prior to screening and written clearance from Cardiologist documented.
-
Hematocrit <30% or >60%
-
History of hepatitis B, hepatitis C, or HIV
-
Current treatment for a seizure disorder unless written clearance by neurologist to participate in study
-
History of adrenal insufficiency
-
Currently receiving (or likely to need during the study period): immunosuppressant therapy; chemotherapy; anticoagulant/antithrombotic therapy (excluding aspirin); glucocorticoids (excluding ophthalmic or nasal). This exclusion does include the use of inhaled glucocorticoids and the use of topical glucocorticoids (over sensor site only); antibiotic for chronic infection (e.g. osteomyelitis, endocarditis)
-
A condition requiring or likely to require magnetic resonance imaging (MRI)
-
Known topical or local anesthetic allergy
-
Known allergy to glucocorticoids
-
Any condition that in the investigator's opinion would make the subject unable to complete the study or would make it not in the subject's best interest to participate in the study. Conditions include but are not limited to psychiatric conditions, known current or recent alcohol abuse or drug abuse by subject history, a condition that may increase the risk of induced hypoglycemia or risk related to repeated blood testing. Investigator will supply rationale for exclusion
-
Participation in another clinical investigation (drug or device) within 2 weeks prior to screening or intent to participate during the study period
-
The presence of any other active implanted device (as defined further in protocol)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | John Muir Physician Network Clinical Research Center | Concord | California | United States | 94520 |
| 2 | AMCR Institute Inc. | Escondido | California | United States | 92025 |
| 3 | Diablo Clinical Research | Walnut Creek | California | United States | 94598 |
| 4 | Barbara Davis Center for Diabetes | Aurora | Colorado | United States | 80045 |
| 5 | Atlanta Diabetes Care | Atlanta | Georgia | United States | 30318 |
| 6 | Rocky mountain Diabetes Center C/O Research Department | Idaho Falls | Idaho | United States | 83404 |
| 7 | Clinical Trials of Texas | San Antonio | Texas | United States | 78229 |
| 8 | Rainier Clinical Research Center | Renton | Washington | United States | 98057 |
Sponsors and Collaborators
- Senseonics, Inc.
Investigators
- Principal Investigator: Satish Garg, MD, Barbara Davis Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CTP-0036